Interpace Biosciences (Interpace Biosciences) Change In Receivables : $-0.65 Mil (TTM As of Dec. 2023)

View and export this data going back to 1998. Start your Free Trial

What is Interpace Biosciences Change In Receivables?

Interpace Biosciences's change in receivables for the quarter that ended in Dec. 2023 was $-0.15 Mil. It means Interpace Biosciences's Accounts Receivable increased by $0.15 Mil from Sep. 2023 to Dec. 2023 .

Interpace Biosciences's change in receivables for the fiscal year that ended in Dec. 2023 was $0.05 Mil. It means Interpace Biosciences's Accounts Receivable declined by $0.05 Mil from Dec. 2022 to Dec. 2023 .

Interpace Biosciences's Accounts Receivable for the quarter that ended in Dec. 2023 was $4.98 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Interpace Biosciences's Days Sales Outstanding for the three months ended in Dec. 2023 was 44.22.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Interpace Biosciences's liquidation value for the three months ended in Dec. 2023 was $-66.84 Mil.

Interpace Biosciences Change In Receivables Historical Data

The historical data trend for Interpace Biosciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Interpace Biosciences Change In Receivables Chart

Interpace Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-1.10

1.73

2.15

-0.13

0.05

Interpace Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-0.24	0.32	-0.81	-	-0.15

Interpace Biosciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.65 Mil.

Interpace Biosciences (OTCPK:IDXG) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Interpace Biosciences's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	4.983	/	10.283	*	91
=	44.22

2. In Ben Graham's calculation of liquidation value, Interpace Biosciences's accounts receivable are only considered to be worth 75% of book value:

Interpace Biosciences's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3.498	-	74.693	+	0.75 * 4.983	+	0.5 * 1.227
=	-66.84

Interpace Biosciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of Interpace Biosciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Interpace Biosciences (Interpace Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (OTCPK:IDXG) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

PF42:Germany

Address

300 Interpace Parkway, Morris Corporate Center 1, Building C, Parsippany, NJ, USA, 07054

Website

https://www.interpace.com

Interpace Biosciences Inc is engaged in the life sciences industry. It provides molecular diagnostics, bioinformatics, and pathology services for the evaluation of the risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first-line assays principally focused on the early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology. It operates under one segment which is the business of developing and selling diagnostic clinical services.

Executives

Christopher Mccarthy	officer: Principal Financial Officer	C/O INTERPACE BIOSCIENCES, INC., 300 INTERPACE PARKWAY; BLDG C, 1ST FLOOR, PARSIPPANY NJ 07054
Vijay Aggarwal	director	2320 SCIENTIFIC PARK DRIVE, WILMINGTON NC 28405
Thomas W. Burnell	director, officer: President and CEO	1355 PEACHTREE STREET, SUITE 1150, ATLANTA GA 30309
Peter H Kamin	10 percent owner	2720 DONALD ROSS ROAD, #311, PALM BEACH GARDENS FL 33410
Fred S. Knechtel	officer: Chief Financial Officer	REMY INTERNATIONAL, INC., 600 CORPORATION DR., PENDLETON IN 46064
Fortunato R. Rocca	director	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE, VISTA CA 92081
Edward Chan	director	C/O 1315 CAPITAL II, L.P., 2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
1315 Capital Ii, L.p.	10 percent owner	2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
Robert J. Gorman	director	C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Laurence Mccarthy	director	2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Ampersand 2018 Limited Partnership	10 percent owner	55 WILLIAM STREET, SUITE 240, WELLESLEY MA 02481
Eric B. Lev	director, 10 percent owner	C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Thomas John Freeburg	officer: Chief Accounting Officer	INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PKWY, BLDG. C, PARSIPPANY NJ 07054
Gregory Richard	officer: Chief Commerical Officer	C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054
Felice Schnoll-sussman	director	C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054